Incyte opened higher at $120.10, compared with its previous close of $116.80. In the last trading session, the stock traded between $119.67 and $122.87. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Incyte is now worth
$ 180.19
giving a profit of
$ 80.19 (80.19%)
Note: Past profits do not guarantee future returns.
Rating from 18 Analysts
Today's Change
+$3.89 (+3.33%)
Day High
$122.87
Day Low
$119.67
Day Open
$120.10
Prev Close
$116.80
Volume
10,77,391
1W Return
3.24%
1M Return
-2.07%
3M Return
-5.03%
6M Return
21.79%
1Y Return
33.83%
Market Cap ($ Mn)
24,464
PE Ratio
15.85
PB Ratio
3.94
PEG Ratio
0.41
ROE
30.48%
ROCE
34.23%
EPS (TTM)
$2.91
1 Week
3.24%
1 Month
-2.07%
3 Months
-5.03%
6 Months
21.79%
9 Months
19.40%
Incyte to present oncology data at ESMO 2026 congress
Incyte presents four rapid oral abstracts at ESMO Congress 2026 in Madrid. Data covers KRAS G12D, TGFβR2×PD-1, and CDK2 inhibitors in GI and ovarian cancers. Investor webcast scheduled for October 26, 2026, at 2:30 pm ET. INCA33890 developed in collaboration with Merus, now part of Genmab A/S.
11 days agoTruist Securities maintains Hold on Incyte, lifts price target to $115
Truist Securities maintains a Hold rating on Incyte Corporation. The price target is raised from $105 to $115. Analyst Srikripa Devarakonda is responsible for the rating and target update.
15 days agoIncyte delivers 17.52% annualized return over past 20 years
Incyte stock returned 17.52% annually over the past 20 years. Performance beat the broader market by 8.29% on an annualized basis. A $1,000 investment from 20 years ago is now worth $26,123.20. The company currently has a market capitalization of $25.75 billion.
2mo agoGVF endorses Incyte's vitiligo awareness campaign
GVF endorses Incyte's *Moments of Clarity* campaign to raise awareness for nonsegmental vitiligo. The initiative features new patient stories emphasizing persistence, advocacy, and confidence. GVF President Dr. Desai praised the campaign for reducing stigma and supporting informed care decisions.
2mo agoIncyte grants 21,556 RSUs and 18,172 options to 24 new hires
Incyte Corporation issued 21,556 RSUs and 18,172 stock options to 24 new employees on August 3, 2026. The awards were approved by the compensation committee under the 2024 Inducement Stock Incentive Plan. Options have an exercise price of $118.43 and a ten-year term, while RSUs vest over four years. The grants comply with Nasdaq Listing Rule 5635(c)(4).
2mo agoIncyte Minjuvi combo gets PBS funding in Australia
Incyte's Minjuvi receives PBS funding in Australia for relapsed or refractory follicular lymphoma. It is the first new reimbursed therapy for this condition in nine years. The chemotherapy-free regimen showed a 57% reduction in disease progression risk in Phase 3 trials, impacting over 10,000 Australians living with the disease.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $540.00 | +1.95% | $1,36,868.94M | 31.55 | |
| $61.07 | +2.12% | $1,31,639.87M | 14.39 | |
| $222.76 | +4.01% | $88,933.81M | - | |
| $818.77 | +0.68% | $82,808.76M | 19.64 | |
| $897.85 | +0.68% | $56,462.20M | 38.99 | |
| $371.56 | -0.48% | $40,792.43M | 65.60 | |
| $190.27 | +0.82% | $40,781.71M | - | |
| $56.49 | -1.40% | $35,253.15M | 26.24 | |
| $65.93 | +1.71% | $29,357.11M | 32.37 | |
| $37.52 | +1.10% | $27,101.56M | - | |
| $111.59 | +15.07% | $24,369.25M | - | |
| $174.00 | -25.13% | $23,282.77M | 39.98 |
An investment of $100 made 5 years ago in Incyte is now worth
$ 180.19
giving a profit of
$ 80.19 (80.19%)
Note: Past profits do not guarantee future returns.
